How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013 ; [Epub ahead of print]Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, Drayson MT, Dispenzieri A, Leung N, International Kidney and Monoclonal Gammopathy Research Group. How I treat monoclonal ...
Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple ...
However, in another scenario, monoclonal gammopathy with unknown significance might be just a precursor to WM based on a recent series showing frequent MYD88 L265P expression in five of nine monoclonal gammopathy with unknown significance cases, showing all clonal plasma cells as well as clonal ...
Allpatientsdiagnosed with myeloma, a cancer of the blood-producing bone marrow, first develop a relatively benign condition called 'monoclonal gammopathy of undetermined significance' or 'MGUS'. MGUS is fairly common in the older population and only progresses to cancer in approximately one in 100 c...
Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple ...
Risk stratification by free-light chain (FLC) ratio, immunoglobulin (Ig) type, and serum monoclonal(M) protein level is warranted. Low-risk patients should have SPEP every 2 to 3 years, while patients with higher-risk MGUS should have SPEP every year (SOR: C, expert opinion)....
Summary Significant advances have been made in our understanding of the natural history, pathogenesis, mechanisms of progression and prognosis of monoclonal gammopathy of undetermined significance (MGUS). Although the overall incidence of MGUS progression is 1 per year, it is now...
How to resolve a clinical and molecular puzzle: concomitant monoclonal gammopathy of undetermined significance (MGUS) with neutrophilia and clonal hematopoiesis of indeterminate potential (CHIP)doi:10.1007/s00277-019-03786-9Simon HaefligerInstitute of PathologyDarius Juskevicius...